Kathleen Tregoning is on the board of Spero Therapeutics, Inc. and Chief Corporate Affairs Officer at Cerevel Therapeutics Holdings, Inc.

In the past she held the position of Executive Vice President-External Affairs at Sanofi and Senior Vice President-Corporate Affairs at Biogen France SAS.

Ms. Tregoning received an undergraduate degree from Stanford University and a graduate degree from Harvard Kennedy School of Government.